Sponsors

Lead Sponsor

Debiopharm International SA

Age

18 - No limit years

Sex

MALE

Healthy Volunteers

No

Inclusion Criteria

•1. Participant with histologically confirmed diagnosis of prostate cancer, with one of the following:
•1. Newly diagnosed androgen-sensitive locally advanced or metastatic disease; or
•2. Localized disease not suitable for local primary intervention with curative intent.
•2. Participant judged by the Study Investigator to be candidate for continuous androgen deprivation therapy (ADT).
•3. Baseline morning serum testosterone levels \>150 ng/dL at screening visit.
•4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
•5. Life expectancy of at least 6 months.
•6. Adequate bone marrow, hepatic, and renal function at the screening visit.
•\[Note: Other protocol and subprotocol-defined criteria apply\]

Exclusion Criteria

•1. Previous ADT (neoadjuvant or adjuvant hormonal therapy) for ≥6 months duration and \<6 months treatment-free interval before start of screening.
•2. Participant requires combination with androgen deprivation therapy with the exception of enzalutamide.
•3. History of bilateral orchiectomy, adrenalectomy, or hypophysectomy.
•4. Received chemotherapy or cryotherapy within 8 weeks prior to the start of screening for the treatment of prostate cancer.
•5. Abnormal cardiovascular function or diabetes.
•6. Use of exogenous testosterone within 6 months before the start of screening.
•7. Major surgery within 4 weeks before the start of screening.
•8. Cancer disease within the last two years except for prostate cancer and some skin cancers.
•\[Note: Other protocol and subprotocol-defined criteria apply\]

Related studies

RECRUITINGPhase 3

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

NCT06274047 · Androgen Axis Suppression, Prostatectomy, and more

RECRUITINGPhase 1/2

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more

RECRUITINGPhase 1/2

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

NCT07226986 · PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy

RECRUITINGNA

CARE Tool Study Aim 3

NCT07296887 · Gynecologic Cancer, Prostate Cancer, and more

RECRUITINGNA

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

NCT06202248 · Non-metastatic Prostate Cancer, Locally Recurrent Prostate Cancer

View all related studies →

A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

CARE Tool Study Aim 3

Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

Trial snapshot

Condition

Locations shown

For caregivers